Chun-Tao Wu
Overview
Explore the profile of Chun-Tao Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Xu J, Wang W, Zhang S, Xu H, Wu C, Qi Z, et al.
Curr Med Chem
. 2018 Apr;
26(40):7196-7211.
PMID: 29651946
Background: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients...
22.
Gao H, Liu L, Qi Z, Xu H, Wang W, Wu C, et al.
Hepatobiliary Pancreat Dis Int
. 2018 Mar;
17(2):95-100.
PMID: 29576277
Background: Immunotherapy has shown promise against solid tumors. However, the clinical significance of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in pancreatic ductal adenocarcinoma (PDAC)...
23.
Liu L, Xu H, He M, Wang W, Wang W, Wu C, et al.
Surgery
. 2018 Mar;
163(6):1280-1294.
PMID: 29548773
Background: We evaluated the application of the latest 8 American Joint Committee on Cancer (AJCC) staging system in Chinese patients and determined whether the addition of biologic markers could improve...
24.
Qi Z, Xu H, Zhang S, Xu J, Li S, Gao H, et al.
Int J Oncol
. 2018 Feb;
52(4):1105-1116.
PMID: 29436617
Pancreatic cancer is a lethal disease with a high metastatic potential. In our previous study, we identified a specific subgroup of patients with pancreatic cancer with a serum signature of...
25.
Xu J, Wang W, Zhang S, Xu H, Wu C, Qi Z, et al.
Ann Surg Oncol
. 2017 Dec;
25(3):647-654.
PMID: 29235006
Background: The role of N classification is controversial in several prognostication systems proposed for pancreatic neuroendocrine neoplasms (pNENs). The widely accepted modified European Neuroendocrine Tumor Society (mENETS) system suggests this...
26.
Xu H, Liu L, Xiang J, Wang W, Qi Z, Wu C, et al.
Surgery
. 2016 Nov;
161(2):373-384.
PMID: 27838102
Background: Carbohydrate antigen (CA19-9) is a well-established marker to monitor disease status after resection of pancreatic cancer. However, few serum markers have been reported to improve the prognostic ability of...
27.
Xiang J, Wang W, Liu L, Xu H, Wu C, Yang J, et al.
Sci Rep
. 2016 May;
6:25115.
PMID: 27174632
No abstract available.
28.
Xiang J, Wang W, Liu L, Xu H, Wu C, Yang J, et al.
Sci Rep
. 2016 Jan;
6:19222.
PMID: 26753987
Patients with pancreatic ductal adenocarcinoma (PDAC) and preoperative CA19-9 ≥ 1,000 U/mL that does not decrease postresection have the worst prognosis, but the mechanism is unclear. Here, we elucidated the...
29.
Liu L, Xu H, Wang W, Wu C, Xiang J, Liu C, et al.
Oncotarget
. 2016 Jan;
7(5):5943-56.
PMID: 26745601
This study evaluated potential of serum tumor markers to predict the incidence and intensity of pancreatic cancer metastasis as well as patient survival. Retrospective records from 905 patients and prospective...
30.
Wu C, Han K, Guo Z, Yang Y, Gao Y, Bai J, et al.
Ultrasound Med Biol
. 2015 Feb;
41(3):654-8.
PMID: 25683218
Contrast-enhanced transcranial Doppler (c-TCD) was performed on 117 patients to detect a right-to-left shunt (RLS). Each patient was examined during normal breathing and after performing the Valsalva maneuver (VM) in...